Cargando…

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

INTRODUCTION: Craniopharyngiomas are one of the most frequently diagnosed hypothalamo-pituitary tumors in childhood. The adamantinomatous histological subtype accounts for most pediatric cases, while the papillary variant is almost exclusively diagnosed in adults. Here, we report a case of papillary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borrill, R., Cheesman, E., Stivaros, S., Kamaly-Asl, I. D., Gnanalingham, K., Kilday, John-Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341153/ https://www.ncbi.nlm.nih.gov/pubmed/30069716 http://dx.doi.org/10.1007/s00381-018-3925-4

Ejemplares similares

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
por: Larkin, Sarah Jane, et al.
Publicado: (2014)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2019)

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
por: Brastianos, Priscilla K., et al.
Publicado: (2014)

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2023)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

The role of artificial intelligence in paediatric neuroradiology
por: Pringle, Catherine, et al.
Publicado: (2022)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation
por: Liang, Songnian, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
por: Ye, Ziheng, et al.
Publicado: (2022)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation
por: Xu, Cheng, et al.
Publicado: (2022)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience
por: Kure, Shoko, et al.
Publicado: (2019)

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
por: Ivković, Irena, et al.
Publicado: (2022)

MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
por: Zheng, Tingting, et al.
Publicado: (2023)

Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
por: Chik, Constance L, et al.
Publicado: (2021)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

Effect of BRAF(V600E )mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model
por: Cahill, Susanne, et al.
Publicado: (2007)

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
por: Paek, Se Hyun, et al.
Publicado: (2017)

High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
por: Espiritu, Gerard Anthony M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6qeib1fjldk82ibqj7u2k4n24k